This assay can be used
- To aid in the management of patients suffering from malignant melanoma (Elecsys S100 assay is not suitablefor the diagnosis of malignant melanoma).
- To aid in the management of patients after potential brain injury in conjunction with clinical information and imaging techniques
Elecsys® technology
ECL (ElectroChemiLuminescence) is Roche’s technology for immunoassay detection. Based on this technology and combined with well-designed, specific and sensitive immunoassays, Elecsys delivers reliable results. The development of ECL immunoassay is based on the use of a ruthenium-complex and tripropylamine (TPA).
The chemiluminescence reaction for the detection of the reaction complex is initiated by applying a voltage to the sample solution, resulting in a precisely controlled reaction. ECL technology can accommodate many immunoassay principles while providing excellent performance.